TN2016000546A1 - Aminoester derivatives - Google Patents

Aminoester derivatives

Info

Publication number
TN2016000546A1
TN2016000546A1 TN2016000546A TN2016000546A TN2016000546A1 TN 2016000546 A1 TN2016000546 A1 TN 2016000546A1 TN 2016000546 A TN2016000546 A TN 2016000546A TN 2016000546 A TN2016000546 A TN 2016000546A TN 2016000546 A1 TN2016000546 A1 TN 2016000546A1
Authority
TN
Tunisia
Prior art keywords
sub
sup
buffer
edta
hci
Prior art date
Application number
TN2016000546A
Other languages
English (en)
Inventor
Gabriele Amari
Elisabetta Armani
Charles Baker-Glenn
Wesley Blackaby
Carmelida Capaldi
Ian Linney
Naimisha Trivedi
De Pöel Hervé Van
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of TN2016000546A1 publication Critical patent/TN2016000546A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
TN2016000546A 2014-06-05 2015-06-03 Aminoester derivatives TN2016000546A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14171266 2014-06-05
PCT/EP2015/062417 WO2015185649A1 (en) 2014-06-05 2015-06-03 Aminoester derivatives

Publications (1)

Publication Number Publication Date
TN2016000546A1 true TN2016000546A1 (en) 2018-04-04

Family

ID=50884281

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2016000546A TN2016000546A1 (en) 2014-06-05 2015-06-03 Aminoester derivatives

Country Status (32)

Country Link
US (2) US9763924B2 (enExample)
EP (1) EP3152201B1 (enExample)
JP (1) JP2017516824A (enExample)
KR (1) KR102420323B1 (enExample)
CN (1) CN106459020B (enExample)
AR (1) AR100732A1 (enExample)
AU (1) AU2015270539B2 (enExample)
BR (1) BR112016026725B1 (enExample)
CA (1) CA2953198C (enExample)
CL (1) CL2016003117A1 (enExample)
CY (1) CY1120698T1 (enExample)
DK (1) DK3152201T3 (enExample)
EA (1) EA032761B1 (enExample)
ES (1) ES2688826T3 (enExample)
GE (1) GEP20186922B (enExample)
HR (1) HRP20181967T1 (enExample)
HU (1) HUE042119T2 (enExample)
IL (1) IL249325B (enExample)
LT (1) LT3152201T (enExample)
MA (1) MA39947B1 (enExample)
MX (1) MX377669B (enExample)
PE (1) PE20161557A1 (enExample)
PH (1) PH12016502221A1 (enExample)
PL (1) PL3152201T3 (enExample)
PT (1) PT3152201T (enExample)
RS (1) RS57787B1 (enExample)
SG (1) SG11201610132RA (enExample)
SI (1) SI3152201T1 (enExample)
TN (1) TN2016000546A1 (enExample)
TW (1) TW201625600A (enExample)
WO (1) WO2015185649A1 (enExample)
ZA (1) ZA201608331B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104532A1 (es) 2015-05-07 2017-07-26 Chiesi Farm Spa Derivados aminoéster como inhibidores de la fosfodiesterasa 4 (pde4) y antagonistas de los receptores m3
AR104822A1 (es) * 2015-06-01 2017-08-16 Chiesi Farm Spa Derivado de aminoésteres
TW201710254A (zh) * 2015-06-01 2017-03-16 吉斯藥品公司 胺基酯衍生物
CN106866474B (zh) * 2017-02-16 2018-12-28 陕西师范大学 一种手性α-芳基甘氨酸酯衍生物的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
PE20091552A1 (es) 2008-02-06 2009-10-25 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
AR093797A1 (es) 2012-12-05 2015-06-24 Chiesi Farm Spa Derivados de feniletilpiridina inhibidores de pde-4
KR20150091061A (ko) 2012-12-05 2015-08-07 키에시 파르마슈티시 엣스. 피. 에이. Pde4-억제제로서 페닐에틸피리딘 유도체
KR20150092173A (ko) 2012-12-05 2015-08-12 키에시 파르마슈티시 엣스. 피. 에이. Pde4-억제제로서 페닐에틸피리딘 유도체
WO2015082619A1 (en) 2013-12-05 2015-06-11 Chiesi Farmaceutici S.P.A. Benzhydryl derivatives for the treatment of respiratory diseases
KR20160086351A (ko) 2013-12-05 2016-07-19 키에시 파르마슈티시 엣스. 피. 에이. 호흡기 질환의 치료를 위한 헤테로아릴 유도체

Also Published As

Publication number Publication date
MA39947B1 (fr) 2018-10-31
WO2015185649A1 (en) 2015-12-10
EP3152201B1 (en) 2018-08-29
RS57787B1 (sr) 2018-12-31
EA032761B1 (ru) 2019-07-31
US20150352091A1 (en) 2015-12-10
PE20161557A1 (es) 2017-02-07
US9763924B2 (en) 2017-09-19
SI3152201T1 (sl) 2018-10-30
ZA201608331B (en) 2018-05-30
TW201625600A (zh) 2016-07-16
PL3152201T3 (pl) 2019-02-28
CN106459020B (zh) 2019-06-18
ES2688826T3 (es) 2018-11-07
PT3152201T (pt) 2018-10-26
JP2017516824A (ja) 2017-06-22
AU2015270539B2 (en) 2018-11-08
IL249325B (en) 2018-12-31
US10117860B2 (en) 2018-11-06
SG11201610132RA (en) 2017-01-27
EP3152201A1 (en) 2017-04-12
MX377669B (es) 2025-03-11
MA39947A (fr) 2017-04-12
BR112016026725B1 (pt) 2024-02-27
LT3152201T (lt) 2018-10-10
CL2016003117A1 (es) 2017-06-23
IL249325A0 (en) 2017-02-28
BR112016026725A8 (pt) 2021-06-29
BR112016026725A2 (pt) 2017-08-15
AR100732A1 (es) 2016-10-26
KR102420323B1 (ko) 2022-07-13
CA2953198C (en) 2023-06-13
KR20170015294A (ko) 2017-02-08
CY1120698T1 (el) 2019-12-11
DK3152201T3 (en) 2018-11-19
AU2015270539A1 (en) 2016-12-22
MX2016015958A (es) 2017-04-10
HUE042119T2 (hu) 2019-06-28
HRP20181967T1 (hr) 2019-02-08
PH12016502221A1 (en) 2017-02-06
US20170340616A1 (en) 2017-11-30
CA2953198A1 (en) 2015-12-10
CN106459020A (zh) 2017-02-22
EA201692227A1 (ru) 2017-05-31
WO2015185649A9 (en) 2017-01-05
GEP20186922B (en) 2018-11-12

Similar Documents

Publication Publication Date Title
PH12016502221A1 (en) Aminoester derivatives
Koehler et al. Expanding the utility of NMR restraints with paramagnetic compounds: background and practical aspects
Farley et al. Identification and quantification of protein posttranslational modifications
CA2868907C (en) Anti-hla-b*27 antibodies and uses thereof
GB2549632A8 (en) Fusion protein comprising three binding domains to 5T4 and CD3
WO2011056975A3 (en) Genetically encoded calcium indicators and methods of use
MY182355A (en) Hmo synthesis
MY156225A (en) Preparation of 6-aminocaproic acid from 5-formyl valeri c acid
WO2013177118A3 (en) Novel purification of non-human antibodies using protein a affinity chromatography
DK1984442T3 (da) Hybrid-kraftpåvirkningsmodifikatorer og fremgangsmåde til fremstilling af disse
MX338443B (es) Metodo para cementacion en una formacion subterranea utilizando una composicion cementosa que contiene micro-cristales de silicato de calcio hidratado.
WO2010039802A3 (en) Methods and compositions for isolating nucleic acid
WO2011077099A3 (en) Methods for the purification of cucurbituril
MX2011009025A (es) Sistema de vector de expresion que comprende dos marcadores de seleccion.
WO2010114239A3 (ko) 도로의 면형 데이터를 이용한 맵 매칭장치 및 그 방법
Sołtysik et al. ERα36–another piece of the estrogen puzzle
WO2010128518A3 (en) Novel process for the preparation of cisatracurium besylate
Jean-Charles et al. Chapter nine-cellular roles of beta-arrestins as substrates and adaptors of ubiquitination and deubiquitination
WO2011143575A3 (en) smFRET WITH MEMBRANE PROTEINS
WO2012168344A8 (en) BINDING COMPOUNDS TO HUMAN β1-ADRENORECEPTOR (β1-AR) AND THEIR USE IN THE MEASUREMENT OF AUTO-ANTI-βA1-AR ANTIBODIES
Campbell et al. Homobivalent conjugation increases the allosteric effect of 9-aminoacridine at the α1-adrenergic receptors
WO2012153089A8 (en) Extraction from cells
WO2013169931A3 (en) Assays and cell-based tests using a receptor na/k-atpase/src complex and uses thereof
WO2009140198A3 (en) Pathogen detection and screening
CN102850641A (zh) 一种耐磨防滑鞋底材料的制备方法